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Abstract
Background: Non- invasive prenatal diagnosis (NIPD) for sickle- cell disorder (SCD) is 
moving closer to implementation and studies considering stakeholder preferences are 
required to underpin strategies for offering NIPD in clinical practice.
Objective: Determine service user and provider preferences for key attributes of pre-
natal diagnostic tests for SCD and examine views on NIPD.
Method: A questionnaire that includes a discrete choice experiment was used to de-
termine the preferences of service users and providers for prenatal tests that varied 
across three attributes: accuracy, time of test and risk of miscarriage.
Results: Adults who were carriers of SCD or affected with the condition (N=67) were 
recruited from haemoglobinopathy clinics at two maternity units. Health profession-
als, predominately midwives, who offer antenatal care (N=62) were recruited from one 
maternity unit. No miscarriage risk was a key driver of decision making for both service 
users and providers. Service providers placed greater emphasis on accuracy than ser-
vice users. Current uptake of invasive tests was 63%, whilst predicted uptake of NIPD 
was 93.8%. Many service users (55.4%) and providers (52.5%) think pressure to have 
prenatal testing will increase when NIPD for SCD becomes available.
Conclusions: There are clear differences between service users and health profession-
als’ preferences for prenatal tests for sickle- cell disorder. The safety of NIPD is wel-
comed by parents and uptake is likely to be high. To promote informed choice, pretest 
counselling should be balanced and not exclusively focused on test safety. Counselling 
strategies that are sensitive to feelings of pressure to test will be essential.
K E Y W O R D S
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1  | BACKGROUND
Sickle- cell disorders (SCD) affect the structure of haemoglobin and re-
sult in episodes of acute pain, chronic anaemia and progressive organ 
damage. Recent improvements in life expectancy for people affected 
with SCD have been attributed to earlier detection and improvements 
in comprehensive management.1 SCD is a relatively common condi-
tion, with approximately 12 000–15 000 affected individuals in the 
UK.2,3 Whilst the condition is most common in people of African ori-
gin, SCD may occur in any ethnic group.3
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SCD is caused by mutations in the β- globin gene. Inheritance is au-
tosomal recessive, so both parents must be carriers of a mutation for 
the baby to be at risk of SCD. In the UK, there is a universal neonatal 
screening programme for SCD and carrier screening is offered through 
an antenatal haemoglobinopathy screening programme that aims to offer 
screening by 10 weeks in pregnancy.4 Prenatal diagnosis of SCD is the 
most frequently requested prenatal test for a single gene disorder in the 
UK,5 and currently requires invasive testing (chorionic villus sampling or 
amniocentesis) which carry a small risk of miscarriage6,7 and can only be 
carried out after 11 weeks in pregnancy. A safe alternative is on the hori-
zon, with proof- of- concept studies showing that non- invasive prenatal 
diagnosis (NIPD) based on analysis of cell- free DNA (cfDNA) in maternal 
plasma may be possible for SCD.8 NIPD can be performed early in preg-
nancy (9- 10 weeks) and requires only a maternal blood sample, thereby 
removing the risk of procedure- related miscarriage associated with inva-
sive diagnostic tests. It is anticipated that NIPD for SCD will be diagnostic 
and there will be no need to confirm NIPD with invasive testing. As such, 
NIPD could be considered as a replacement for invasive testing.
It is important that research exploring views of NIPD is carried out 
alongside the technical development of these new tests to ensure that 
social and ethical issues are addressed and stakeholder needs are met. 
Previous research exploring views of NIPD for single gene disorders, 
including SCD, has been undertaken using qualitative interviews and 
focus groups with carriers of single gene disorders and health profes-
sionals.9–11 To expand this work, we have utilized a quantitative ap-
proach that includes a discrete choice experiment (DCE). DCEs allow 
us to look closely at people’s decision- making processes when making 
choices about prenatal testing. This is done by giving participants a se-
ries of hypothetical options for prenatal tests with differing attributes 
and asking them to choose between them. Analysing the choices, they 
make will identify the test attributes that are most important for de-
cision making. We will also gain insights into people’s willingness to 
trade one attribute for another. DCEs have been used to reveal pref-
erences for screening and diagnostic tests for Down syndrome,12–17 
and we have also used a DCE to look at preferences for the prenatal 
diagnosis of cystic fibrosis.18 Here, we used a DCE to explore service 
user and health professional preferences for three key attributes of 
prenatal diagnostic tests for SCD: accuracy, time of test and risk of 
miscarriage. We also examined views on NIPD, including expected up-
take. We tested two hypotheses:
1. Service users and health professionals will differ in their pref-
erences for the three attributes of prenatal tests to be examined: 
safety, accuracy and time of testing;
2. Service users will value the safety afforded by NIPD and hypotheti-
cal uptake of the test will be high.
2  | METHOD
2.1 | Ethical approval
Ethical approval was obtained from a National Research Ethics Service 
Committee (10/H0714/3).
2.2 | Recruitment
Two groups of participants were recruited: (i) service users: adults who 
were either carriers of SCD or affected with the condition, aged 18 
or over and attending haemoglobinopathy antenatal clinics at either 
St Thomas’s Hospital or University College London Hospital, and (ii) 
service providers: health professionals who deliver antenatal care and 
see women with pregnancies at risk of SCD at St Thomas’ Hospital.
Convenience sampling was used to participants to the study. For 
the service users, group potential participants were invited to anony-
mously complete the questionnaire whilst waiting for their clinical ap-
pointment. For the service provider group, potential participants were 
approached in person in their workplace and invited to anonymously 
complete a hard copy of the questionnaire.
2.3 | Questionnaire design
The questionnaire had three components: (i) DCE choice sets, (ii) 
structured questions about prenatal testing and NIPD and (iii) demo-
graphic questions. Questionnaire design has been described previ-
ously, as the questionnaire used here was a modified version of the 
questionnaire used in our previous study looking at prenatal testing 
for cystic fibrosis.18 Briefly, design of the choice sets followed DCE 
guidelines19–21 and the attributes of safety, accuracy and time of test 
results were derived from focus groups with carriers of single gene 
disorders (SCD, cystic fibrosis and thalassaemia).10 The attributes and 
levels used in the DCE choice sets are presented in Table 1. There 
were eight choices in the DCE. One choice set served as an inter-
nal consistency check as one test was clearly better than the other. 
Participants had the choice of Test A, Test B or neither (Table 1). The 
structured questions comprised the following: ranking five attributes 
of prenatal tests (early testing, accuracy, financial cost, safety and 
comprehensive information) and a series of questions gathering views 
on prenatal testing for SCD which included two free- text questions on 
benefits and concerns about NIPD. Demographic questions for ser-
vice users covered age, gender, ethnicity, education and number of 
TABLE  1 Discrete choice experiment design
(A) Attributes and levels used in the discrete choice experiment
Attribute Levels
Accuracy 90%, 95%, 98, 100%
Time of results (gestation in weeks) 8, 10, 12, 14
Risk of miscarriage Small risk (1%), No risk
(B) Example of a discrete choice experiment choice set
Choice 1 Test A Test B
Accuracy 95% 100%
Time of results 10 wk 12 wk
Risk of miscarriage Small risk (1%) No risk
Which test would you prefer (tick one box only)?
Test	A	□ Test	B	□ Neither	□
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children. Demographic questions for health professionals covered job 
title, years in role, age and gender.
2.4 | Analysis
DCE analysis followed published guidance.19–21 The DCE prefer-
ence data were analysed using a conditional logit regression model 
as previously described.18	 As	 the	 sign	 (+	 or	 −)	 of	 the	 coefficients	
from the regression analysis shows the direction of the preference, 
we expected positive coefficients for accuracy and no miscarriage 
risk and a negative coefficient for timing, which would indicate a 
preference for earlier test. Notably, as the different attributes do 
not have the same unit of change, the absolute value of the coef-
ficients cannot be directly compared. Consequently, to compare the 
preferences of service users and service providers, a common scale 
was created by calculating the marginal rates of substitution (MRS) 
as a ratio of the coefficients of two attributes.20 Descriptive statis-
tics was used for the other components of the questionnaire. The 
software package Stata 12.0 (StataCorp USA) was used to perform 
all analyses.
3  | RESULTS
3.1 | Participants
Questionnaires were completed by 78 service users and 62 health 
professionals. Questionnaires were excluded if the internal con-
sistency question was incorrect (patients n=7, health professionals 
n=0) or if the choice set was incomplete (patients n=4, and health 
professionals n=0). Ultimately, 67 service user and 62 health pro-
fessional questionnaires were included in the analysis. The service 
user group included carriers of SCD (88.2%) and people affected 
with the condition (18.8%). The majority were female (89.4%). 
A small proportion had a child with SCD (16.4%). Health profes-
sionals were predominately midwives (88.1%) and female (91.8%). 
Demographic information for service users and providers is sum-
marized in Tables 2 and 3.
3.2 | Regression results
Service users and providers prefer a test with greater accuracy, early 
testing and no risk of miscarriage (Table 4). The direction of the pref-
erences matched our a priori expectations and supports the validity 
of the models. All coefficients were statistically significant for ser-
vice providers. For service users, coefficients for accuracy and risk 
of miscarriage were significant, but time of results was not. Service 
providers placed greater value on test accuracy than service users, but 
no difference was seen for test safety or time of results. Analysis of 
participants’ willingness to trade between attributes was determined. 
For service users, 35 (52.2%) chose tests that carried no risk of mis-
carriage for all options, five (7.5%) chose tests with the highest accu-
racy for all options and one (1.5%) chose tests with the earliest time. 
For health professionals, 11 (17.7%) chose tests that carried no risk 
of miscarriage for all options, four (6.5%) chose tests with the highest 
accuracy for all options and none chose solely based on test timing.
3.3 | Marginal rates of substitution
The MRS demonstrates the strong preference held by both service 
users and health professionals for a test with no risk of miscarriage. 
Notably, service users were prepared to wait longer and accept lower 
accuracy compared to service providers for a test that had no risk of 
miscarriage (Table S1).
3.4 | Ranking of attributes
Participants ranked the importance of five attributes of prenatal tests: 
safety, early testing, accuracy, financial cost and comprehensive infor-
mation (Tables S2 and S3). Safety was ranked highest by service users 
(43.2%) followed by full information (21.6%). Accuracy was ranked 
highest by health professionals (45.6%) followed by safety (42.1%). 
Cost was ranked lowest by both service users (86.5%) and health pro-
fessionals (57.9%).
3.5 | Views on prenatal testing and the 
introduction of NIPD
When service users were asked whether they would have invasive 
testing for SCD, 63.1% said they have had or are likely to have inva-
sive testing, with the most common reasons for testing being to “help 
make a decision about whether or not to continue the pregnancy” 
(47.4%) and “to plan and prepare for the possible birth of a baby with 
SCD” (36.8%) (Table 5). More than half (53.8%) said they would never 
have an invasive test because of the risk of miscarriage. When asked 
TABLE  2 Health professional demographic data
Total 
(n=62)
Age in years
Mean (SD) 36.8 (9.15)
Gender
Female 56 (91.8%)
Male 5 (8.2%)
Profession
Midwife 42 (88.1%)
Consultant 4 (6.8%)
Specialist nurse 1 (1.7%)
Sonographer 2 (3.4%)
Years in profession
≤5 29 (47.5%)
6- 15 23 (37.7%)
16- 25 9 (14.8%)
In some cases, numbers may not add up to total N due to missing data.
Percentages may not add up to 100 due to rounding.
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whether they would have NIPD for SCD if it was available, 93.8% 
indicated that they would have NIPD. The majority of service users 
(73.4%) said that they would be prepared to pay for NIPD.
All participants were asked their views on pressure to have pre-
natal testing for SCD and whether they felt that offering NIPD would 
increase feelings of pressure to have a diagnostic test (Table 6). 
Approximately half of both the service users (55.4%) and health pro-
fessionals (52.5%) thought that pressure to have prenatal testing 
would increase if NIPD for SCD became available. Half of the service 
providers (50%) and more than half of service users (57.1%) felt that 
there was already pressure to have prenatal testing for SCD. The most 
frequently cited source of pressure was health professionals for both 
service users (46.5%) and providers (36.9%).
Forty- three (64.2%) service users responded to the question on 
what they saw as the benefits of NIPD. These primarily fell into three 
categories: no miscarriage risk (n=21); decision making, knowledge 
and preparation (n=17); and simpler and less stressful testing (n=6). 
Fifty- nine (95.2%) health professionals described potential benefits 
of NIPD, with the majority mentioning decision making, knowledge 
and preparation (n=46); no miscarriage risk (n=15); and early diagnosis 
(n=11). Forty- five service users reported that they had no concerns 
(67.2%) and five said they had concerns but did not elaborate. Twenty- 
nine (46.8%) health professionals reported that they had no concerns. 
Twenty- six (41.9%) health professionals described concerns, with the 
most common being increased pressure to test and terminate (n=11), 
availability of appropriate counselling (n=7), accuracy (n=6) and costs 
(n=4).
To address the question of whether health professionals thought 
NIPD should only be offered if it would change pregnancy manage-
ment, a question was included asking whether NIPD should only be 
offered to women considering termination of pregnancy. Only four 
(6.6%) strongly agreed or agreed compared to 57 (93.4%) who strongly 
disagreed or disagreed.
4  | DISCUSSION
The aim of this study was to determine the preferences held by po-
tential service users and providers for prenatal tests for SCD. Test 
safety was an important driver of decision making for both groups. 
Differences were evident in the emphasis placed on test accuracy, 
with service providers placing greater emphasis on this attribute than 
service users. It was clear that service users were prepared to wait 
longer and accept lower accuracy than service providers for a test 
with no risk of miscarriage. In addition, over half of the service users 
chose tests based only on test safety and did not consider the other 
attributes. Differences between health professionals and potential 
service users have been seen in other DCE studies comparing non- 
invasive and invasive tests for cystic fibrosis18 and also for Down 
syndrome.15–17 Our findings draw attention to the need for health 
professionals to be mindful that their own views on what is important 
when making decisions about prenatal testing may differ from those 
held by parents. Moreover, the emphasis on test safety when mak-
ing decisions about prenatal testing points towards the possibility that 
parents may not make an informed choice as other attributes may not 
be considered. Consequently, it is important that health profession-
als discuss the benefits and limitations of NIPD, taking care not to 
focus solely on discussing the safety of the test. Alternatives to NIPD 
should also be discussed in a balanced way and must include the op-
tion of not having testing. Formal consent processes could also be 
used to emphasize that NIPD is a diagnostic test that needs careful 
consideration.11,22,23
TABLE  3 Service user demographic data
Total (n=67)
Carrier status
 Carrier of sickle- cell disorder 52 (81.2%)
 Affected with sickle- cell disorder 12 (18.8%)
Gender
 Female 59 (89.4%)
 Male 7 (10.6%)
Age in years
 Mean (SD) 32.2 (5.46)
Ethnicity
 African/Caribbean 62 (92.5%)
 Other 5 (7.5%)
Highest qualification
 No qualification 3 (4.7%)
 High school 9 (14.1%)
 Some college or other training 7 (10.9%)
 Degree or equivalent 45 (70.3%)
Relationship status
 Married/In a relationship 54 (80.6%)
 Separated/Divorced 5 (7.5%)
 Widowed 1 (1.5%)
 Single 7 (10.4%)
Religious faith
 Yes 62 (93.9%)
 No 4 (6.1%)
Currently pregnant
 Yes 64 (97.0%)
 No 2 (3.0%)
Number of children
 None 25 (37.9%)
 1 22 (33.3%)
 2 13 (19.7%)
 3 or more 6 (9.1%)
Child with sickle- cell disorder?
 Yes 9 (16.4%)
 No 46 (83.6%)
In some cases, numbers may not add up to total N due to missing data.
Percentages may not add up to 100 due to rounding.
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Previous research looking at NIPD for single gene disorders 
found that both potential service users and providers thought that 
the ease and safety of NIPD may put couples under increased pres-
sure to have prenatal testing.9,10,18 Similarly, we found that approx-
imately half of service users (55.4%) and providers (52.5%) felt that 
offering NIPD would increase pressure to have a prenatal test to 
diagnose SCD. Moreover, the DCE results demonstrate that test 
safety is a key driver of decisions for parents considering prenatal 
testing. Service providers offering NIPD for SCD need to be aware 
that offering NIPD may create feelings of pressure to have diag-
nostic testing. The most commonly reported source of pressure was 
health professionals and it may be that feelings of pressure arise 
from how the test is presented or because it has been offered by a 
“trusted” health professional.24 This is particularly pertinent in offer-
ing NIPD for SCD as previous research with women offered carrier 
testing for SCD during pregnancy indicated that the woman in the 
study accepted that health professionals had authoritative knowl-
edge and the fact that screening was offered implied that having 
a baby with SCD would not be a good outcome.25 Careful pretest 
counselling is needed to avoid parents feeling pressured to test and 
to allow them to make choices in keeping with their personal beliefs 
and values.
We found that willingness to have NIPD was high, with over 
90% of service users saying they would have NIPD for SCD if it was 
available compared to 63% who said they would currently choose 
invasive testing. In addition, approximately 50% reported that risk of 
miscarriage was a barrier to invasive prenatal testing. These findings 
are similar to those of other studies exploring the potential uptake 
of NIPD for single gene disorders.9,10,18,26 Previous research has 
highlighted the difficulties in achieving timely partner testing within 
the UK Sickle Cell and Thalassaemia Screening Programme.27 In 
2013- 2014, 15281 pregnant women were screen positive and 64% 
of partners had carrier screening.28 It is possible that the number 
of women opting for NIPD for SCD may increase further because 
women whose partners decline carrier testing may find NIPD more 
acceptable than invasive testing when the exact risk of the child 
inheriting SCD is unknown.10,11 Overall, it appears that uptake of 
NIPD for single gene disorders will be high and many couples who 
would not consider invasive testing due to the risk of miscarriage 
would have NIPD.
The changes to the population accepting the offer of prenatal 
testing need to be considered in our approaches to counselling for 
NIPD for SCD. Most notably, many couples who would not previously 
have had prenatal testing may take up NIPD, and as a result may find 
themselves faced with a decision about termination of pregnancy. 
This issue is particularly important in the setting of prenatal testing 
for SCD where in the UK and other countries a prenatal carrier screen-
ing programme is in place and there are existing concerns about in-
formed consent processes29 and carrier screening being presented as 
TABLE  4 Conditional logit regression comparing service users and health professionals
Accuracy Time of results No risk of miscarriage
Coefficient (95% CI) Coefficient (95% CI) Coefficient (95% CI)
Service users (n=67)a 0.114 (0.074 to 0.154) −0.047c	(−0.108	to	−0.013) 1.760 (1.509 to 2.011)
Health professionals (n=62)b 0.304 (0.243 to 0.365) −0.130	(−0.192	to	−0.068) 1.768 (1.422 to 2.113)
Difference (P- value) <.0001 .0661 .9717
CI- confidence interval.
aNumber of observations=1605; pseudo- R2=.4438.
bNumber of observations=1488; pseudo- R2=.5161.
cCoefficient not significant. All other coefficients significant P<.0001.
TABLE  5 Service user uptake of prenatal testing
Total (n=67)
Have had/likely to have an invasive test for SCD
Strongly agree/Agree 41 (63.1%)
Strongly disagree/Disagree 24 (36.9%)
Reason for choosing to have a diagnostic test
To plan and prepare for the possible birth of a baby 
with SCD
14 (36.8%)
To help make a decision about whether or not to 
continue the pregnancy
18 (47.4%)
Because my family or my partner would want me to 1 (2.6%)
Because it is offered as part of the antenatal 
service
5 (13.4%)
Other 0 (0%)
Would never have an invasive test because would not consider 
termination of pregnancy
Strongly agree/Agree 28 (45.2%)
Strongly disagree/Disagree 34 (54.8%)
Would never have an invasive test because of the risk of miscarriage
Strongly agree/Agree 35 (53.8%)
Strongly disagree/Disagree 30 (46.2%)
Would have NIPD if available
Strongly agree/Agree 60 (93.8%)
Strongly disagree/Disagree 4 (6.3%)
Willingness to pay for NIPD
≤£50 37 (57.8%)
£100-	200 8 (12.5%)
≥£200 2 (3.1%)
Not prepared to pay 17 (26.6%)
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routine.30 Without careful pretest counselling, the addition of NIPD to 
the care pathway has the potential to undermine informed consent as 
women newly identified as carriers of SCD may see NIPD as routine 
next step following a positive carrier screening result.31 As such, it will 
be especially important to allow sufficient time in pretest counselling 
to talk through the impact of having NIPD which includes a discussion 
around the implications of the possible test results that is guided by 
the parents values and preferences.32 It must be made clear to parents 
that accepting a “simple blood test” could lead to a decision about 
whether to continue or terminate the pregnancy. Individualized sup-
port through post- test counselling to assist decisions about next steps 
will be essential.
The cost of NIPD for SCD will need to be considered in strategies 
to implement this test in the NHS. The potential cost of NIPD relative 
to the current invasive testing pathway has been explored and NIPD 
for	SCD	using	current	approaches	was	estimated	to	cost	£1210,	which	
was	£190	more	than	invasive	testing.	Moreover,	the	anticipated	high	
uptake of NIPD we found in this study (approximately 95% compared 
to 65% for invasive testing) would result in an incremental cost of 
NIPD	over	invasive	testing	of	£48,635	per	100	pregnancies	at	risk	of	
SCD. As the increased uptake will include parents who would want to 
have NIPD for information only and would not consider termination of 
pregnancy, there is a need to address the issue of whether it is appro-
priate to direct resources to test when pregnancy management would 
not change. Consideration of this question must include the benefits 
of the information for early reassurance or for planning and prepa-
ration if the baby is found to be affected by SCD.31 In the study, we 
report here only a very small proportion of health professionals (6.6%), 
when asked, thought NIPD should only be offered if it would change 
pregnancy management.
4.1 | Limitations
Several limitations of our study may mean that our findings are not 
widely generalizable. Recruitment was only conducted at two cen-
tres for service users and only one centre for service providers and 
both centres were located in central London. As this was not a ran-
dom sample and convenience sampling was used, it is possible that 
sampling bias will limit the generalizability of our results. In addition, 
participants were self- selected and there may be responder bias to-
wards people with strong pre- existing views on NIPD. Another limita-
tion of the study was that the numbers of participants recruited were 
not sufficient to allow subgroup comparisons. In an equivalent study 
looking at NIPD for cystic fibrosis, we found there were differences 
in preferences between people affected with the condition and those 
who were carriers.18 In addition, only a small number of men were re-
cruited and their viewpoints may differ to those of women. The health 
professional group primarily comprised midwives and health profes-
sionals from other training backgrounds may have different prefer-
ences. In future studies, it would be useful to seek the views of other 
professionals and include people with both obstetrics and genetics 
backgrounds. As this is a stated preference study, it is possible that 
the choices made by participants may not reflect real- life decisions. 
The DCE only included three attributes of prenatal tests, and in reality, 
many attributes are considered when making decisions about testing. 
In addition, the DCE design does not address why these choices have 
been made or give insight into how the tests were perceived. Another 
important limitation is that participants’ reported willingness to have 
NIPD is hypothetical and may not reflect uptake when the test enters 
clinical practice which has been seen in other studies looking at up-
take of genetic testing.33–35
5  | CONCLUSIONS
When making decisions about prenatal testing for SCD, potential 
service users and providers do not place the same emphasis on the 
test attributes. It is likely that the safety of NIPD will be welcomed by 
parents and uptake will be high. It is therefore important that pretest 
counselling is balanced and not predominately focused on the safety 
of NIPD. Care must also be taken to minimize feelings of pressure to 
have NIPD. Considerations for implementation need to include cur-
rent carrier screening and prenatal diagnosis pathways. Offering NIPD 
as a next step in the current pathway could create pressure to test at 
a time when news of carrier status is still being processed and deci-
sions need to be made quickly about next steps. Thorough pre- and 
post- test counselling will be essential and NIPD should be offered by 
health professionals specifically trained in counselling for prenatal 
testing for SCD.
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TABLE  6 Views on pressure to have prenatal testing
Service users 
(n=67)
Health 
professionals 
(n=62)
There is pressure on women at risk of having a child with SCD to have 
a diagnostic test in pregnancy
Strongly agree/Agree 36 (57.1%) 30 (50.0%)
Strongly disagree/Disagree 27 (42.9%) 30 (50.0%)
If you agree, where do you think this pressure comes from*
Partner 6 (14.0%) 6 (9.2%)
Family members 9 (20.9%) 15 (23.1%)
Health professionals 20 (46.5%) 24 (36.9%)
Society in general 5 (11.6%) 10 (15.4%)
Your cultural or religious 
community
2 (4.9%) 10 (15.4%)
Other 1 (2.3%) 0 (0%)
The availability of NIPD will increase pressure to have prenatal testing
Strongly agree/Agree 31 (55.4%) 31 (52.5%)
Strongly disagree/Disagree 25 (44.6%) 28 (47.5%)
*Participants could choose multiple responses.
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